2021. Commentary about open-label randomized controlled study of ivermectin in mild to moderate COVID-19. IMC Journal of Medical Science. 14, 2 (Apr. 2021), 67–68. DOI:https://doi.org/10.3329/imcjms.v14i2.52833.